Abstract
Type I interferons (IFNs) represent a group of cytokines that act through a common receptor composed by two chains (IFNAR-1 and IFNAR-2). Several in vitro and in vivo studies showed a potent antitumor activity induced by these cytokines. IFN-, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of cancer cell growth and differentiation, affecting cellular communication and signal transduction pathways. IFN-, is currently the most used cytokine in the treatment of cancer. However, the potential anti-tumour activity of IFN- is limited by the activation of tumour resistance mechanisms. This article reviews the current knowledge about the antitumor activity of type I IFNs, focusing on new potential strategies able to strengthen the antitumor activity of these cytokines.
Keywords: Type I interferons, interferon-alpha, interferon-beta, STATs, mTOR, pegylated interferons, farnesyltransferase inhibitors, EGF-R, cytokine, antitumor activity
Protein & Peptide Letters
Title:Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties
Volume: 20 Issue: 4
Author(s): Michele Caraglia, Alessandra Dicitore, Monica Marra, Sara Castiglioni, Luca Persani, Pasquale Sperlongano, Pierosandro Tagliaferri, Alberto Abbruzzese and Giovanni Vitale
Affiliation:
Keywords: Type I interferons, interferon-alpha, interferon-beta, STATs, mTOR, pegylated interferons, farnesyltransferase inhibitors, EGF-R, cytokine, antitumor activity
Abstract: Type I interferons (IFNs) represent a group of cytokines that act through a common receptor composed by two chains (IFNAR-1 and IFNAR-2). Several in vitro and in vivo studies showed a potent antitumor activity induced by these cytokines. IFN-, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of cancer cell growth and differentiation, affecting cellular communication and signal transduction pathways. IFN-, is currently the most used cytokine in the treatment of cancer. However, the potential anti-tumour activity of IFN- is limited by the activation of tumour resistance mechanisms. This article reviews the current knowledge about the antitumor activity of type I IFNs, focusing on new potential strategies able to strengthen the antitumor activity of these cytokines.
Export Options
About this article
Cite this article as:
Caraglia Michele, Dicitore Alessandra, Marra Monica, Castiglioni Sara, Persani Luca, Sperlongano Pasquale, Tagliaferri Pierosandro, Abbruzzese Alberto and Vitale Giovanni, Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties, Protein & Peptide Letters 2013; 20 (4) . https://dx.doi.org/10.2174/0929866511320040005
DOI https://dx.doi.org/10.2174/0929866511320040005 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prevention of Cancer in the Upper Gastrointestinal Tract with COX-Inhibition. Still an Option?
Current Pharmaceutical Design Diterpenoids- Potential Chemopreventive and Chemotherapeutic Agents in Leukemia
Current Pharmaceutical Biotechnology Substance Abuse, HIV-1 and Hepatitis
Current HIV Research Activation of Integrin β1 Mediates the Increased Malignant Potential of Ovarian Cancer Cells Exerted by Inflammatory Cytokines
Anti-Cancer Agents in Medicinal Chemistry Advanced Neoplastic Disease as Immunologic, Endocrine and Metabolic Disorder
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Molecular Mechanisms Regulating Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Sp/KLF Family and Tumor Angiogenesis in Pancreatic Cancer
Current Pharmaceutical Design Free Radicals in Diseases and Potential Role of Phytoconstituents-A Cause with Emerging Importance
Current Chemical Biology Molecular Diagnosis in Autoimmune Skin Blistering Conditions
Current Molecular Medicine Emerging Molecular Functions of MicroRNA-9: Cancer Pathology and Therapeutic Implications
Anti-Cancer Agents in Medicinal Chemistry Subcellular Analysis of the Platelet Proteome
Current Proteomics Role of PARP Inhibitors in Cancer Biology and Therapy
Current Medicinal Chemistry Effect of Formulations of Nanosized Quercetin Liposomes on COX-2 and NF-kB in MCF-10A Cells
Pharmaceutical Nanotechnology Role of Nitric Oxide in Physiology and Pathology of the Gastrointestinal Tract
Mini-Reviews in Medicinal Chemistry Role of Glucocorticoids in Breast Cancer
Current Pharmaceutical Design Valproic Acid Metabolism and its Consequences on Sexual Functions
Current Drug Metabolism Perspectives of Benzimidazole Derivatives as Anticancer Agents in the New Era
Anti-Cancer Agents in Medicinal Chemistry Reactive Oxygen Species in Cancer Biology and Anticancer Therapy
Current Medicinal Chemistry Plasticity of T Cell Differentiation and Cytokine Signature: A Double-Edged Sword for Immune Responses
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)